insights_auto
Why is AGIO up 3,34%?
Dive Deeperchevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
32,82 USD
arrow_upward
+3,34%(+1,06) 1D
33,00 USD
arrow_upward
+0,55% (+0,18)bedtimeAfter hours
Closed: 11-ноя., 16:00:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
31,99 USD
High
33,12 USD
Low
31,53 USD
Mkt. cap
1,96 млд
Avg. vol.
1,31 млн
Volume
844,74 миң
52-wk high
45,99 USD
52-wk low
22,24 USD
EPS
-6,32 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
Open
31,99 USD
High
33,12 USD
Low
31,53 USD
Mkt. cap
1,96 млд
Avg. vol.
1,31 млн
Volume
844,74 миң
52-wk high
45,99 USD
52-wk low
22,24 USD
EPS
-6,32 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
News stories
From web sources and news partners
TradingView
·
2 күн мурун
Weekly Recap: Q3 product revenue rises and FDA delays mitapivat review
Yahoo Finance
·
4 күн мурун
Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc